Developments in ophthalmology · 2010
Antivascular endothelial growth factors in anterior segment diseases.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Scholl Stefan, Kirchhof Janna, Augustin Albert J
Аннотация
Proangiogenic growth factors, mainly VEGF (vascular endothelial growth factor) play a significant role in anterior segment diseases, characterized by neovascularization. Newly grown vessels in the cornea can lead to an impairment of transparency and visual acuity. Neovascularization of the iris (rubeosis iridis) and the anterior chamber angle are caused by ischemic retinopathies, usually leading to neovascular glaucoma with serious loss of vision. A pterygium is characterized, amongst others, by fibrovascular proliferation and may have vision threatening consequences if left untreated. Several antiangiogenic drugs have evolved in the last decade, mainly used for the treatment of choroidal neovascularization in age-related macular degeneration. Bevacizumab though, is also widely used off-label, in topic form or as an intracameral injection, to treat anterior segment neovascularization with encouraging results.
Предметные рубрики MeSH
Administration, TopicalAngiogenesis InhibitorsAnterior Eye SegmentAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabConjunctivaCorneal NeovascularizationEye DiseasesGlaucoma, NeovascularHumansInjections, IntraocularIrisIschemiaNeovascularization, PathologicPterygiumRetinal VesselsVascular Endothelial Growth Factor AVision Disorders